Amycretin
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Amycretin is a dual amylin/GLP-1 receptor agonist being investigated for obesity and type 2 diabetes. It binds to both amylin and GLP-1 receptors, activating Gs proteins to increase cAMP, which stimulates insulin secretion, reduces appetite, delays gastric emptying, and reduces glucagon secretion.
Primary Uses
obesity
type 2 diabetes
weight loss
blood glucose reduction
reduced food intake
Protocol Reference
Dose
Not provided
Evidence
Clinical trials ongoing
Also in Metabolic